Meeting
2024 ASCO Genitourinary Cancers Symposium
Impact of a rash management guide on incidence and severity of rash with apalutamide: Experience from the Apa-RP study in high-risk localized prostate cancer.
Authors
Neal D. Shore
Carolina Urologic Research Center, Myrtle Beach, SC
Neal D. Shore , Jason Hafron , Daniel Saltzstein , Amitabha Bhaumik , Pankaj Aggarwal , Rushikesh Potdar , Jennifer Phillips , Tracy McGowan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care
Clinical Trial Registration Number
NCT04523207
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 316)
DOI
10.1200/JCO.2024.42.4_suppl.316
Abstract #
316
Poster Bd #
N7
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Prostate-specific antigen (PSA) kinetics in patients (pts) with advanced prostate cancer treated with apalutamide: Results from the TITAN and SPARTAN studies.
First Author: Kim N. Chi
Poster
2024 ASCO Genitourinary Cancers Symposium
Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: A multicenter, open-labeled, single-arm phase II trial.
First Author: Junlong Zhuang
Poster
2024 ASCO Genitourinary Cancers Symposium
Neoadjuvant pamiparib plus abiraterone and ADT for high-risk/very high-risk localized prostate cancer: Results of a prospective study.
First Author: Junlong Zhuang
Poster
2023 ASCO Annual Meeting
Digital histopathology-based multimodal artificial intelligence scores predict risk of progression in a randomized phase III trial in patients with nonmetastatic castration-resistant prostate cancer.
First Author: Felix Y Feng